<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39321175</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>No impact of COVID-19 at delivery on maternal mortality or infant adverse birth outcomes in Botswana during the Omicron era.</ArticleTitle><Pagination><StartPage>e0310980</StartPage><MedlinePgn>e0310980</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0310980</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0310980</ELocationID><Abstract><AbstractText>SARS-CoV-2 infection during pregnancy was associated with maternal mortality and adverse birth outcomes in the pre-Omicron era, including a stillbirth rate of 5.6% in Botswana. We re-evaluated these outcomes in the Tsepamo Study during the Omicron era. We assessed maternal mortality and adverse birth outcomes for all singleton pregnancies from mid-November 2021 (the start of the Omicron era) to mid-August 2022 at nine Tsepamo sites, among individuals with documented SARS-CoV-2 screening PCR or antigen tests and known HIV status. Of 9,705 women routinely screened for SARS-CoV-2 infection at delivery (64% of deliveries at these sites), 373 (3.8%) tested positive. Women with HIV were as likely to test positive for SARS-CoV-2 (77/1833, 4.2%) as women without HIV (293/6981, 4.2%) (p = 1.0). There were 5 recorded maternal deaths (0.03%), one occurring in a woman with a positive SARS-CoV-2 test result. In contrast, maternal mortality was 3.7% and 0.1% in those with and without SARS-CoV-2, respectively, during the pre-Omicron era. In the Omicron era, there were no differences among infants exposed or unexposed to SARS-CoV-2 in overall adverse birth outcomes (28.1% vs 29.6%; aRR 1.0, 95%CI 0.8-1.1), severe adverse birth outcomes (11.9 vs 10.6%; aRR 1.1, 95%CI 0.8-1.5), preterm delivery (15.1% vs 14.9%; aRR 1.0, 95%CI 0.8-1.3), or stillbirth (1.9% vs 2.3%; aRR 0.8, 95%CI 0.4-1.7). Adverse outcomes among those exposed to both HIV and SARS-CoV-2 were similar to those exposed to HIV alone (31.2% vs. 33.1%; aRR 0.9, 95%CI 0.6-1.3; p = 0.5). Maternal mortality was far lower in Botswana during the Omicron era than in the pre-Omicron era, and adverse birth outcomes were no longer significantly impacted by exposure to SARS-CoV-2 either overall or with HIV co-exposure. Increased population immunity to SARS-CoV-2, less stress on the hospital systems in the Omicron era, and possible differences in viral pathogenicity may combine to explain these findings.</AbstractText><CopyrightInformation>Copyright: © 2024 Banga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banga</LastName><ForeName>Jaspreet</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1479-3721</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson-Gibson</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diseko</LastName><ForeName>Modiegi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caniglia</LastName><ForeName>Ellen C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayondi</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabuta</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luckett</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moyo</LastName><ForeName>Sikhulile</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3821-4592</Identifier><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith-Lawrence</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ministry of Health and Wellness, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosepele</LastName><ForeName>Mosepele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lockman</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makhema</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zash</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Botswana Harvard Health Partnership, Gaborone, Botswana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001902" MajorTopicYN="N" Type="Geographic">Botswana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008428" MajorTopicYN="Y">Maternal Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050497" MajorTopicYN="N">Stillbirth</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39321175</ArticleId><ArticleId IdType="pmc">PMC11423995</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0310980</ArticleId><ArticleId IdType="pii">PONE-D-23-42780</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boettcher LB, Metz TD. Maternal and neonatal outcomes following SARS-CoV-2 infection. Semin Fetal Neonatal Med. 2023;28(1):101428. doi: 10.1016/j.siny.2023.101428</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.siny.2023.101428</ArticleId><ArticleId IdType="pmc">PMC10005973</ArticleId><ArticleId IdType="pubmed">37105860</ArticleId></ArticleIdList></Reference><Reference><Citation>Eltayeb MM, Mohamad RMA, Alhawiti IS, Alsulami GM, Buraei S, Mohammed SSH, et al.. Neonatal Outcome of Mothers With COVID-19 in King Salman Armed Forces Hospital, Tabuk, Kingdom of Saudi Arabia. Cureus. 2023;15(9):e45257. doi: 10.7759/cureus.45257</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.45257</ArticleId><ArticleId IdType="pmc">PMC10576630</ArticleId><ArticleId IdType="pubmed">37842358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajbhiye RK, Sawant MS, Kuppusamy P, Surve S, Pasi A, Prusty RK, et al.. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2021;155(1):48–56. doi: 10.1002/ijgo.13793</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.13793</ArticleId><ArticleId IdType="pmc">PMC7612435</ArticleId><ArticleId IdType="pubmed">34160059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko JY, DeSisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et al.. Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis. Clin Infect Dis. 2021;73(Suppl 1):S24–s31. doi: 10.1093/cid/ciab344</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab344</ArticleId><ArticleId IdType="pmc">PMC8136045</ArticleId><ArticleId IdType="pubmed">33977298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al.. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status—United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641–7. doi: 10.15585/mmwr.mm6944e3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6944e3</ArticleId><ArticleId IdType="pmc">PMC7643892</ArticleId><ArticleId IdType="pubmed">33151921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mndala L, Monk EJM, Phiri D, Riches J, Makuluni R, Gadama L, et al.. Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform. Lancet Glob Health. 2022;10(11):e1623–e31. doi: 10.1016/S2214-109X(22)00359-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00359-X</ArticleId><ArticleId IdType="pmc">PMC9553200</ArticleId><ArticleId IdType="pubmed">36155136</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock SJ, Moore E, Calvert C, Carruthers J, Denny C, Donaghy J, et al.. Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. Lancet Respir Med. 2022;10(12):1129–36. doi: 10.1016/S2213-2600(22)00360-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00360-5</ArticleId><ArticleId IdType="pmc">PMC9708088</ArticleId><ArticleId IdType="pubmed">36216011</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson-Gibson M, Diseko M, Caniglia EC, Mayondi GK, Mabuta J, Luckett R, et al.. Association of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection With Maternal Mortality and Neonatal Birth Outcomes in Botswana by Human Immunodeficiency Virus Status. Obstet Gynecol. 2023;141(1):135–43. doi: 10.1097/AOG.0000000000005020</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000005020</ArticleId><ArticleId IdType="pmc">PMC10462386</ArticleId><ArticleId IdType="pubmed">36701614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mupanomunda M, Fakih MG, Miller C, Ottenbacher A, Winegar AL, Roberts P, et al.. Comparison of Severe Maternal Morbidities Associated With Delivery During Periods of Circulation of Specific SARS-CoV-2 Variants. JAMA Netw Open. 2022;5(8):e2226436. doi: 10.1001/jamanetworkopen.2022.26436</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.26436</ArticleId><ArticleId IdType="pmc">PMC9375165</ArticleId><ArticleId IdType="pubmed">35960519</ArticleId></ArticleIdList></Reference><Reference><Citation>Seasely AR, Blanchard CT, Arora N, Battarbee AN, Casey BM, Dionne-Odom J, et al.. Maternal and Perinatal Outcomes Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Obstet Gynecol. 2022;140(2):262–5. doi: 10.1097/AOG.0000000000004849</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004849</ArticleId><ArticleId IdType="pmc">PMC10336737</ArticleId><ArticleId IdType="pubmed">35852277</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaton CL, Cohen A, Henninger EM, Gendlina I, Hou W, Bernstein PS, et al.. Coronavirus Disease 2019 (COVID-19) Perinatal Outcomes Across the Pandemic at an Academic Medical Center in New York City. Obstet Gynecol. 2023;141(1):144–51. doi: 10.1097/AOG.0000000000004978</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004978</ArticleId><ArticleId IdType="pubmed">36302251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al.. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy. JAMA Pediatr. 2017;171(10):e172222. doi: 10.1001/jamapediatrics.2017.2222</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.2222</ArticleId><ArticleId IdType="pmc">PMC5726309</ArticleId><ArticleId IdType="pubmed">28783807</ArticleId></ArticleIdList></Reference><Reference><Citation>Botswana Ministry of Health &amp; Wellness. Botswana COVID-19 Guideline 8: Management of COVID-19 in Pregnancy in Botswana, v1. Gaborone: Ministry of Health &amp; Wellness; 6 May 2020.</Citation></Reference><Reference><Citation>Dip SD, Sarkar SL, Setu MAA, Das PK, Pramanik MHA, Rubayet Ul Alam, ASM, et al.. Evaluation of RT-PCR assays for detection of SARS-CoV-2 variants of concern. Sci Rep. 2023. Feb 9; 13(1):2342. doi: 10.1038/s41598-023-28275-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-28275-y</ArticleId><ArticleId IdType="pmc">PMC9910272</ArticleId><ArticleId IdType="pubmed">36759632</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.globalpointofcare.abbott/gb/en/product-details/panbio-covid-19-ag-antigen-test.html [Internet]. Panbio COVID-19 Ag Rapid Test Device; c2024 [cited 2024 Jul 26].</Citation></Reference><Reference><Citation>https://www.sdbiosensor.com/product/product_view?product_no=295 [Internet]. Standard Q COVID-19 Ag Home Test; c2021 [cited 2024 Jul 26].</Citation></Reference><Reference><Citation>Blondel B, Kogan MD, Alexander GR, Dattani N, Kramer MS, Macfarlane A, et al.. The impact of the increasing number of multiple births on the rates of preterm birth and low birthweight: an international study. Am J Public Health. 2002;92(8):1323–30. doi: 10.2105/ajph.92.8.1323</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.92.8.1323</ArticleId><ArticleId IdType="pmc">PMC1447238</ArticleId><ArticleId IdType="pubmed">12144992</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo AD, La J, Wu JT, Strymish JM, Ronan M, Brophy M, et al.. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. JAMA Netw Open. 2022;5(10):e2240037. doi: 10.1001/jamanetworkopen.2022.40037</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.40037</ArticleId><ArticleId IdType="pmc">PMC9585432</ArticleId><ArticleId IdType="pubmed">36264571</ArticleId></ArticleIdList></Reference><Reference><Citation>Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. 2022;22(5):277–82. doi: 10.1038/s41577-022-00703-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00703-6</ArticleId><ArticleId IdType="pmc">PMC8931577</ArticleId><ArticleId IdType="pubmed">35304596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193(16):E540–e8. doi: 10.1503/cmaj.202604</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.202604</ArticleId><ArticleId IdType="pmc">PMC8084555</ArticleId><ArticleId IdType="pubmed">33741725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J, et al.. Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic. JAMA Netw Open. 2021;4(8):e2120456. doi: 10.1001/jamanetworkopen.2021.20456</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.20456</ArticleId><ArticleId IdType="pmc">PMC8358731</ArticleId><ArticleId IdType="pubmed">34379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Auger N, Healy-Profitós J. Omicron in pregnancy: time to breathe easier? Lancet Respir Med. 2022;10(12):1101–2. doi: 10.1016/S2213-2600(22)00390-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00390-3</ArticleId><ArticleId IdType="pmc">PMC9544937</ArticleId><ArticleId IdType="pubmed">36216009</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikari EH, MacDonald L, SoRelle JA, Morse J, Pruszynski J, Spong CY. COVID-19 Cases and Disease Severity in Pregnancy and Neonatal Positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) Variant Predominance. JAMA. 2022;327(15):1500–2. doi: 10.1001/jama.2022.4356</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.4356</ArticleId><ArticleId IdType="pmc">PMC8949750</ArticleId><ArticleId IdType="pubmed">35325015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertagnolio S, Inzaule S, Silva R, Thwin SS, Jassat W, Ford N, et al. High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19. IAS 2023: The 12th IAS Conference on HIV Science; 23–26 July 2023; Brisbane. Abstract #OALBC0604.</Citation></Reference><Reference><Citation>Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, et al.. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023;401(10375):447–57. doi: 10.1016/S0140-6736(22)02467-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02467-9</ArticleId><ArticleId IdType="pmc">PMC9910845</ArticleId><ArticleId IdType="pubmed">36669520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022;7(1):151. doi: 10.1038/s41392-022-01009-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01009-8</ArticleId><ArticleId IdType="pmc">PMC9077027</ArticleId><ArticleId IdType="pubmed">35525870</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al.. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706–14. doi: 10.1038/s41586-022-04474-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al.. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700–5. doi: 10.1038/s41586-022-04462-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al.. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603(7902):715–20. doi: 10.1038/s41586-022-04479-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>